TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04403789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Time
Description: Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Group Exercise
Description: The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
Study: NCT05493969

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
Description: Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
Study: NCT01255501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04919057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GelPOINT®
Description: The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
Study: NCT06403020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block
Description: qadratus lumboroum (QL) block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block
Description: qadratus lumboroum (QL) block
Study: NCT01802541

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: triacylglycerol oil
Study: NCT05560152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqihuayu Decotion
Description: Per os, twice a day, for 7 days.
Study: NCT05522296

Intervention type: DRUG
Intervention: Mpox Vaccine
Description: Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
Study: NCT06520696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MILC application
Description: Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect.
Study: NCT05650463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
Study: NCT04808791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102 (Trifluridine/Tipiracil)
Description: Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor
Study: NCT05210088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxia, intermittent
Description: The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia, intermittent
Description: The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxia
Description: The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
Study: NCT05498935

Intervention type: OTHER
Intervention: CPB time
Description: Cardiopulmonary bypass time

Intervention type: OTHER
Intervention: CPB time
Description: Cardiopulmonary bypass time
Study: NCT04483141

Intervention type: DIAGNOSTIC_TEST
Intervention: Abbey Pain Scale
Description: Hetero-assessment of pain

Intervention type: DIAGNOSTIC_TEST
Intervention: Abbey Pain Scale
Description: Hetero-assessment of pain
Study: NCT05511376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AURICULAR VAGUS NERVE STIMULATION
Description: For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE
Description: Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
Study: NCT05787275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic positioning
Description: Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
Study: NCT05480982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive functional therapy via tele rehabilitation
Description: Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates via tele rehabilitation
Description: Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
Study: NCT04099355

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 5mg Cap
Description: 1 QAM and 2 QHS PO 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 5mg Cap
Description: 1 QAM and 2 QHS PO 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-active comparator
Description: 1 QAM and 2 QHS PO 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-active comparator
Description: 1 QAM and 2 QHS PO 14 days
Study: NCT05787275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: incentive spirometer
Description: Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Traditional medical treatment
Study: NCT06120387

Intervention type: PROCEDURE
Intervention: Radical surgery
Description: Radical nephroureterectomy
Study: NCT05111197

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
Study: NCT06120387

Intervention type: RADIATION
Intervention: Kidney sparing surgery+Postoperative radiotheray
Description: Kidney sparing surgery+Postoperative radiotheray
Study: NCT04898595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discontinuation of CRRT
Description: Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
Study: NCT05622110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive glue closure
Description: Incision closure with adhesive glue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular closure
Description: Incision closure with 3-0 vicryl subcuticular sutures
Study: NCT05713526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth service
Description: Researchers will send educational materials (video and e-brochures) about childhood vaccinations to the participants' mobile phones at regular intervals, answer their questions over the phone and send reminder messages before the vaccination appointment.
Study: NCT05876663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping will be applied for 6 weeks and it will be changed with new one after every two days
Study: NCT05075018

Intervention type: OTHER
Intervention: Observational
Description: Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
Study: NCT05821478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy
Description: a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymecyclin and corresponding placebos of the experimental arm
Description: 12-week course of oral lymecycline.
Study: NCT05621499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg，iv，d1，q3w，a total of 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 or 8mg/kg，po，qd，a total of 3 cycles
Study: NCT05876663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy protocol
Description: Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy protocol
Description: Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks.
Study: NCT05353010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 5mg (1 mg \* 5 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A001(Tegoprazan)
Description: IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A001(Tegoprazan) + Tacrolimus
Description: IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
Study: NCT04706286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000 mg
Description: CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000 mg
Description: CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
Study: NCT04935424

Intervention type: DEVICE
Intervention: ApolloVue® S100 Image System (Apollo Medical Optics)
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
Study: NCT06337253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine plus amodiaquine
Description: Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.
Study: NCT05641090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking in water
Description: Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No exercise intervention
Description: This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
Study: NCT05590832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity of Whatsapp messages
Description: Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
Study: NCT04899388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Block
Description: regional anaesthia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Erector Spinae Plane Block
Description: regional anaesthia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: intavenous
Study: NCT04992650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Fat grafting
Study: NCT06047483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRF2105 patch
Description: HRF2105 patch ，external use，once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen patch
Description: Loxoprofen patch ，external use，once a day
Study: NCT05234372

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mivacunaLA
Description: Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mivacunaLA
Description: Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
Study: NCT04626284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart Transplantation
Description: Heart Transplantation
Study: NCT06093958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Manual loading of the chest wall
Description: The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
Study: NCT05594771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural needle
Description: the loading dose for labor analgesia administrated via epidural needle before the catheter insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: the loading dose for labor analgesia administrated via epidural catheter
Study: NCT05523830

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT05786534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Seaweed
Description: 400 mg per day